Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 7/20 | 0.34 |
| ▸ | CA2 | P00918 | 7/20 | 0.34 |
| ▸ | CA4 | P22748 | 7/20 | 0.34 |
| ▸ | CA9 | Q16790 | 7/20 | 0.34 |
| ▸ | CCKAR | P32238 | 4/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341024 | 0.91 | NR1H2 (0.38) | — | |
| SCHEMBL3495634 | 0.85 | ALDH1A1 (0.34) | KMT2ACCKARMAT2A | |
| SCHEMBL3495015 | 0.84 | NR1H2 (0.48) | CA1CA2CA4CA9 | |
| SCHEMBL3493284 | 0.84 | TP53 (0.34) | CCKARMAT2AUSP2 | |
| SCHEMBL3493409 | 0.78 | CCKAR (0.37) | CA1CA2CA4CA9CCKAR | |
| SCHEMBL8229917 | 0.77 | NR1H2 (0.57) | CA1CA2CA4CA9 | |
| SCHEMBL13340903 | 0.76 | CKS1B (0.38) | KMT2A | |
| SCHEMBL13341021 | 0.75 | CKS1B (0.37) | THRB | |
| SCHEMBL3495135 | 0.72 | MAT2A (0.49) | KMT2AMAT2AUSP2 | |
| SCHEMBL3493459 | 0.72 | CA1 (0.45) | CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | KMT2A 952/4885CA1 2606/4885CA2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.